Shanghai Henlius Biotech, Inc.
2696
Rang în acțiuni
#4232
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise,... Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Preț acțiune
$6.91
Capitalizare de piață
$3.77B
Schimbare (1 zi)
3.25%
Schimbare (1 an)
-26.86%
Țară
CN
Tranzacționează Shanghai Henlius Biotech, Inc. (2696)
Categorie
Healthcare
Istoricul spliturilor pentru Shanghai Henlius Biotech, Inc. (2696)
Acțiunea Shanghai Henlius Biotech, Inc. (simbol: 2696) a trecut printr-un total de 0 splituri.
Cel mai recent split a avut loc pe Oct 21, 2026.
O acțiune 2696 cumpărată înainte de Oct 21, 2026 este echivalentă astăzi cu 0 acțiuni 2696.
Cel mai recent split a avut loc pe Oct 21, 2026.
O acțiune 2696 cumpărată înainte de Oct 21, 2026 este echivalentă astăzi cu 0 acțiuni 2696.
Listă splituri acțiuni
| An | Split | Multiplu | Multiplu cumulativ |
|---|---|---|---|
| Nu sunt suficiente date pentru perioada selectată. | |||
Splituri pentru companii similare sau competitori
| Companie | Număr total de splituri | Multiplu cumulativ | Țara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
